Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The OxWell School Survey 2021 highlights that younger children and adolescents are the least willing to have the COVID-19 vaccination. These young people come from the most socioeconomically deprived backgrounds, feel less belonging to their school community and think they have probably had COVID-19 already.

4 young people wearing face masks with school books/bags standing together

Research conducted at the University of Oxford, with collaborators from UCL and the University of Cambridge found that 36% of 9-year-olds are willing to have a COVID-19 vaccination, compared to 51% of 13-year-olds, and 78% of 17-year-olds. The study included over 27,000 students from 180 schools across Berkshire, Buckinghamshire, Oxfordshire, and Merseyside.

Published in EClinicalMedicine, this is the only large-scale study to ask children and adolescents about their willingness to be vaccinated against COVID-19. The research highlights a need for more resources to help young people feel confident and encouraged to take the COVID-19 vaccine, should it be made available and offered to them.

Associate Professor Mina Fazel, Department of Psychiatry, University of Oxford, said:

 

'Our survey findings show that children become more willing to have the COVID-19 vaccine as they get older. Younger children more often defer to their parents, or primary caregivers, for decisions about healthcare and vaccination, but our data shows how important it is for good quality, accessible information to be provided to better enable our younger populations to understand more about the COVID-19 vaccine and its effects.'

The researchers conclude that it is important to provide information to those communities and individuals who are not naturally connected with their schools, as well as making sure that the vaccination can be offered in a variety of different locations to improve access to those who might find it difficult to get to vaccination sites because of location or timing constraints. There may be some young people who value their privacy and may prefer to be able to have a vaccination without letting others around them know about their choice to get vaccinated.

As vaccination programmes for COVID-19 are rolled out to school populations, more available resources are needed to ensure school students feel the vaccine is safe. In addition, health messaging about vaccine safety and its effects on children:

  • needs to be targeted to both school-aged children, and also to their parents/caregivers,
  • must be delivered and provided in a format, and in locations, where diverse members of the population will be able to see it,
  • and should be effectively shared by trusted sources on social media, as survey findings show that the young people who are most hesitant about having the vaccine use social media more.

Dr Simon R White, Senior Research Associate, University of Cambridge, said:

 

‘Our data shows that there are similarities with adult populations in that those from more deprived socioeconomic backgrounds are more hesitant to have the vaccine. Therefore, targeting parents and caregivers with information and materials, which specifically address the worries they might have for their children is important.’  

Professor Russell Viner, UCL Great Ormond Street Institute of Child Health, said:

 

'Our findings suggest it will be essential to reach out and engage with young people from poorer families and communities with lower levels of trust in vaccination and the health system.  A school-based vaccination program, as planned in England, is an important way of helping reduce these health disparities. However, the teenagers who are least engaged with their school communities may need additional support for us to achieve the highest uptake levels.'

Funding received from the Westminster Foundation to the Department of Psychiatry, University of Oxford, the National Institute for Health Research (NIHR) Applied Research Collaboration Oxford and Thames Valley and the NIHR Biomedical Research Centre, both at the Oxford Health NHS Foundation Trust.

To read the full paper, Willingness of children and adolescents to have a COVID-19 vaccination: results of a large whole schools' survey in England.

NIHR OXFORD HEALTH BIOMEDICAL RESEARCH CENTRE NEWS

Please follow the link below to read the news on the NIHR BRC website.

Similar stories

Treating mental illness with electricity - new podcast

A new wave of treatments that stimulate the brain with electricity are showing promise on patients and in clinical trials.

The risk of seizures and epilepsy is higher after COVID than after the flu

Professor Arjune Sen, Nuffield Department of Clinical Neurosciences, on new research suggesting that though the overall risk of seizures is small, it is greater after COVID

Hours of gaming not negatively impacting wellbeing of most adolescents - new study

University of Oxford researchers found that although many school-age adolescents are spending considerable time gaming, it is not having a negative impact on their wellbeing.

Few mental health apps make it to real world, according to new Oxford University study

Despite enthusiasm for digital technology in addressing young people’s mental health, few effective apps have been successfully rolled out.

Oxford gets £122m funding for healthcare research

Health and care research in Oxford is to receive £122 million in government funding over the next five years to improve diagnosis, treatment and care for NHS patients.

Dementia research - new trial with diabetes drug

An important new trial will test the effects of oral semaglutide on the build-up of a protein in the brain that characterises Alzheimer's disease.